Roche invests billions in the US. Nevertheless, there is still enough money for a replacement new building in Basel.
The pharmaceutical company Roche is building a new production facility at its Basel headquarters. At the same time, management is lamenting that Switzerland has lost ground, particularly in terms of taxes.
Roche is building a new production facility at its Basel headquarters, investing 790 million francs in a plant to produce active ingredients for chemically manufactured medications. The facility, set to start production in 2030, will produce new products, including the breast cancer medication Giredestrant and the multiple sclerosis treatment Fenebrutinib.
Meanwhile, Roche is investing heavily in the US, with 50 billion dollars pledged for various projects, including a new factory in Oregon and a research center in Boston. The company's CEO, Thomas Schinecker, expressed concerns that Switzerland is losing its attractiveness due to its tax environment, which he believes is less competitive compared to countries like Ireland and the US.
Written by urgent.news from NZZ Wirtschaft's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
